Edwards Lifesciences Buy Hold or Sell Recommendation

EW -- USA Stock  

USD 153.28  1.10  0.72%

Allowing for the 30-days total investment horizon, and your above average risk tolerance our recommendation regarding Edwards Lifesciences Corporation is 'Hold'. Macroaxis provides Edwards Lifesciences Corporation buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Edwards Lifesciences positions. The advice algorithm takes into account all of Edwards Lifesciences Corporation available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Edwards Lifesciences buy-and-hold prospective. Additionally see Edwards Lifesciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.

Time Horizon

Risk Tolerance

Execute Advice

Edwards Lifesciences Current Recommendation



Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Edwards Lifesciences Corporation has a risk adjusted performance of 0.01, jensen alpha of 0.0, total risk alpha of 0.0, sortino ratio of 0.589 and treynor ratio of 0.0
Macroaxis provides buy, hold, or sell suggestion on Edwards Lifesciences to complement and cross-verify current analyst consensus on Edwards Lifesciences Corporation. Our buy, hold, or sell recommendation engine determines the organization potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Edwards Lifesciences is not overpriced, please confirm all Edwards Lifesciences fundamentals including its EBITDA, Earnings Per Share, Z Score, as well as the relationship between Debt to Equity and Total Asset . Given that Edwards Lifesciences has Price to Earning of 58.93 times, we urge you verify Edwards Lifesciences Corporation market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Edwards Lifesciences Thematic Classifications

Obamacare Repeal IdeaObamacare Repeal
Large healthcare related equities associated with Obamacare
Medical Equipment IdeaMedical Equipment
USA Equities from Medical Equipment industry as classified by Fama & French
Health Management IdeaHealth Management
Healthcare providers, hospitals

Returns Distribution Density

Mean Return0.50Value At Risk1.12
Potential Upside2.42Standard Deviation1.19
 Return Density 

Institutional Investors

Security TypeSharesValue
Vanguard Group IncCommon Shares21.3 M3 B
Blackrock IncCommon Shares15.7 M2.2 B
State Street CorpCommon Shares8.4 M1.2 B
Bank Of New York Mellon CorpCommon Shares8 M1.1 B
Sands Capital Management LlcCommon Shares6.5 M910 M
Wellington Management Group LlpCommon Shares6.3 M873 M
Fmr LlcCommon Shares5.1 M704.7 M

Edwards Lifesciences Greeks

Alpha over DOW
Beta against DOW=0.00
Overall volatility
Information ratio =0.42

Edwards Lifesciences Volatility Alert

Edwards Lifesciences Corporation has low volatility with Treynor Ratio of 0.0, Maximum Drawdown of 3.99 and kurtosis of 0.32. However, we advice all investors to further analyze Edwards Lifesciences Corporation to make certain all market information is desiminated and is consistent with the current expectations about Edwards Lifesciences upside potential.
 Better Than Average     
 Worse Than Average Compare Edwards Lifesciences to competition

Edwards Lifesciences Fundamental Vs Peers

FundamentalsEdwards LifesciencesPeer Average
Return On Equity18.70 % (15.17) %
Return On Asset11.51 % (15.64) %
Profit Margin16.25 % (5.50) %
Operating Margin30.64 % (10.91) %
Current Valuation31.7 B152.14 B
Shares Outstanding210.78 M1.43 B
Shares Owned by Insiders3.94 % 6.91 %
Number of Shares Shorted4.5 M3.24 M
Price to Earning58.93 times40.69 times
Price to Book9.94 times14.44 times
Price to Sales9.36 times17.81 times
Revenue3.45 B9.85 B
Gross Profit2.56 B21.75 B
EBITDA1.06 B1.41 B
Net Income560 M517.71 M
Cash and Equivalents1.5 B3.89 B
Cash per Share7.11 times5.17 times
Total Debt1.05 B7.36 B
Debt to Equity32.40 % 0.72 %
Current Ratio2.07 times3.30 times
Book Value Per Share15.40 times13.64 times
Cash Flow from Operations552.36 M1.25 B
Short Ratio3.92 times2.09 times
Earnings Per Share2.60 times2.30 times
Price to Earnings To Growth2.45 times1.22 times
Number of Employees12.2 K10.67 K
Market Capitalization32.27 B29.78 B
Total Asset4.06 B126.86 B
Retained Earnings3.91 B38.24 B
Working Capital1.57 B3.58 B
Current Asset2.05 B36.8 B
Current Liabilities476.2 M33.34 B
   Acquisition by Huimin Wang of 41500 shares of Edwards Lifesciences subject to Rule 16b-3 [view details]

Edwards Lifesciences Market Momentum

Edwards Lifesciences Alerts

Trading Alerts and Improvement Suggestions
Edwards Lifesciences has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its debt commitments
Latest headline from MacroaxisInsider: Sale by Bessler Anita of 3600 shares of Edwards Lifesciences

Did You Try This Idea?

Run Personal Services Thematic Idea Now
Personal Services
Personal Services Idea
Fama and French focus on testing asset pricing under different economic assumptions. Personal Services theme has 61 constituents.
View All  Next Launch Personal Services
Additionally see Edwards Lifesciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.